{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:50:06Z","timestamp":1791571806372,"version":"4.3.4"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jconrel.2023.01.084","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T07:57:12Z","timestamp":1675929432000},"page":"312-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Nanoparticles of VAV1 siRNA combined with LL37 peptide for the treatment of pancreatic cancer"],"prefix":"10.1016","volume":"355","author":[{"given":"Majd","family":"Agbaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Jbara-Agbaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etty","family":"Grad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meital","family":"Ben-David-Naim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Aizik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gershon","family":"Golomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.01.084_bb0005","first-page":"209","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0010","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0015","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s13277-015-3223-7","article-title":"Pancreatic cancer: diagnosis and treatments","volume":"36","author":"Li","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08277-7","article-title":"Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach","volume":"21","author":"Chun","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0025","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","article-title":"The pancreas cancer microenvironment","volume":"18","author":"Feig","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1758834012446008","article-title":"Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer","volume":"4","author":"Dimou","year":"2012","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071338","article-title":"Pancreatic ductal adenocarcinoma: current and evolving therapies","volume":"18","author":"Adamska","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0040","doi-asserted-by":"crossref","first-page":"28731","DOI":"10.18632\/oncotarget.5086","article-title":"VAV1: a Dr. Jekyll and Mr. Hyde protein-good for the hematopoietic system, bad for cancer","volume":"6","author":"Katzav","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109438","article-title":"VAV1 mutations: what makes them oncogenic?","volume":"65","author":"Farago","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0050","doi-asserted-by":"crossref","first-page":"9214","DOI":"10.18632\/oncotarget.2400","article-title":"VAV1 promotes lung cancer growth by instigating tumor-microenvironment cross-talk via growth factor secretion","volume":"5","author":"Sebban","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0055","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.18632\/oncotarget.2011","article-title":"High nuclear level of VAV1 is a positive prognostic factor in early invasive breast tumors: a role in modulating genes related to the efficiency of metastatic process","volume":"5","author":"Grassilli","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0060","article-title":"Estrogen induces VAV1 expression in human breast cancer cells","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11060-012-0936-y","article-title":"Expression of VAV1 in the tumour microenvironment of glioblastoma multiforme","volume":"110","author":"Garcia","year":"2012","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0070","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.cellsig.2014.05.015","article-title":"VAV1 increases Bcl-2 expression by selective activation of Rac2-Akt in leukemia T cells","volume":"26","author":"Wan","year":"2014","journal-title":"Cell. Signal."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0075","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4161\/cbt.4.5.1781","article-title":"VAV1: a new target in pancreatic cancer?","volume":"4","author":"Denicola","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0080","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-3103","article-title":"Targeting pancreatic cancer metastasis by inhibition of VAV1, a driver of tumor cell invasion","volume":"75","author":"Razidlo","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0085","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000661","article-title":"VAV1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice","volume":"3","author":"Salaymeh","year":"2020","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0090","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/j.1460-2075.1989.tb08354.x","article-title":"VAV, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells","volume":"8","author":"Katzav","year":"1989","journal-title":"EMBO J."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0095","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cub.2013.11.013","article-title":"VAV1 as a central regulator of invadopodia assembly","volume":"24","author":"Razidlo","year":"2014","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ccr.2004.11.024","article-title":"Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis","volume":"7","author":"Fernandez-Zapico","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.trsl.2019.07.006","article-title":"Efficient nanocarriers of siRNA therapeutics for cancer treatment","volume":"214","author":"Subhan","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040442","article-title":"Targeted siRNA nanoparticles for mammary carcinoma therapy","volume":"11","author":"Ben-David-Naim","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0120","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tips.2020.08.004","article-title":"Paving the road for RNA therapeutics","volume":"41","author":"Dammes","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/biotech11010006","article-title":"Non-viral vectors for delivery of nucleic acid therapies for cancer","volume":"11","author":"Kanvinde","year":"2022","journal-title":"Biotech"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2014.01.008","article-title":"Systemic siRNA delivery to a spontaneous pancreatic tumor model in transgenic mice by PEGylated calcium phosphate hybrid micelles","volume":"178","author":"Pittella","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0135","article-title":"Co-delivery of HIF1 alpha siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer","volume":"280","author":"Zhao","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0140","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1166\/jbn.2016.2269","article-title":"A nanoparticle carrier for co-delivery of gemcitabine and small interfering RNA in pancreatic cancer therapy","volume":"12","author":"Li","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0145","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/cas.13267","article-title":"Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy","volume":"108","author":"Li","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1021\/acsnano.9b03978","article-title":"Stromal modulation and treatment of metastatic pancreatic cancer with local intraperitoneal triple miRNA\/siRNA nanotherapy","volume":"14","author":"Xie","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101638","article-title":"RNAi-based approaches for pancreatic cancer therapy","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0160","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.addr.2012.08.014","article-title":"RNAi-based nanomedicines for targeted personalized therapy","volume":"64","author":"Daka","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","article-title":"Strategies, design, and chemistry in siRNA delivery systems","volume":"144","author":"Dong","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0170","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1242\/jcs.066399","article-title":"Breaking down the barriers: siRNA delivery and endosome escape","volume":"123","author":"Dominska","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0175","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of siRNA therapeutics: barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0180","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.gt.3302425","article-title":"RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo","volume":"12","author":"Urban-Klein","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0185","series-title":"Polymers and Nanomaterials for Gene Therapy","first-page":"29","article-title":"2 - PEI and its derivatives for gene therapy","author":"Remant Bahadur","year":"2016"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/srep44134","article-title":"Size matters for in vitro gene delivery: investigating the relationships among complexation protocol, transfection medium, size and sedimentation","volume":"7","author":"Pezzoli","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0195","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1208\/ps040312","article-title":"Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell cultures","volume":"4","author":"Florea","year":"2002","journal-title":"AAPS Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0200","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1021\/bc025529v","article-title":"Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system","volume":"13","author":"Petersen","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0205","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.biomaterials.2006.09.026","article-title":"Cytotoxicity of polyethyleneimine (PEI), precursor base layer of polyelectrolyte multilayer films","volume":"28","author":"Brunot","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0210","first-page":"23","article-title":"Cytotoxic impacts of linear and branched polyethylenimine nanostructures in A431 cells","volume":"1","author":"Kafil","year":"2011","journal-title":"Bioimpacts"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0215","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1039\/c3tb00024a","article-title":"The effect of the gene carrier material polyethyleneimine on the structure and function of human red blood cells in vitro","volume":"1","author":"Li","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0220","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1021\/bc800065f","article-title":"Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity","volume":"19","author":"Zintchenko","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0225","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0230","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.1039\/c2jm15625c","article-title":"High efficiency and low toxicity of polyethyleneimine modified pluronics (PEI-pluronic) as gene delivery carriers in cell culture and dystrophic mdx mice","volume":"22","author":"Wang","year":"2012","journal-title":"J. Mater. Chem."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0235","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1049\/mnl.2017.0457","article-title":"Effect of PEI surface modification with PEG on cytotoxicity and transfection efficiency","volume":"13","author":"Saqafi","year":"2018","journal-title":"Micro Nano Lett."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0240","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cis.2017.12.006","article-title":"A review on cationic lipids with different linkers for gene delivery","volume":"253","author":"Zhi","year":"2018","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0245","article-title":"A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes","volume":"32","author":"Ramishetti","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0250","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle covid-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0260","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles horizontal line from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100428","article-title":"Synthetic molecule libraries for nucleic acid delivery: design parameters in cationic\/ionizable lipids and polymers","volume":"42","author":"Kim","year":"2022","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0270","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.addr.2016.06.008","article-title":"Peptides for nucleic acid delivery","volume":"106","author":"Lehto","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0275","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.0105-2896.2004.0124.x","article-title":"Anti-microbial peptides: from invertebrates to vertebrates","volume":"198","author":"Bulet","year":"2004","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0280","doi-asserted-by":"crossref","first-page":"17951","DOI":"10.1074\/jbc.M311440200","article-title":"The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis","volume":"279","author":"Sandgren","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0285","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.bbamem.2009.12.011","article-title":"Dual functions of the human antimicrobial peptide LL-37-target membrane perturbation and host cell cargo delivery","volume":"1798","author":"Zhang","year":"2010","journal-title":"Biochim. Biophys. Acta.-Biomembr."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0290","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/jgm.696","article-title":"Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis","volume":"7","author":"Akinc","year":"2005","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0295","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejpb.2018.05.034","article-title":"The proton sponge hypothesis: fable or fact?","volume":"129","author":"Vermeulen","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0300","article-title":"The human cathelicidin peptide LL-37 inhibits pancreatic cancer growth by suppressing autophagy and reprogramming of the tumor immune microenvironment","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0305","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8100379","article-title":"VAV1 down-modulates AKT2 expression in cells from pancreatic ductal adenocarcinoma: nuclear VAV1 as a potential regulator of AKT related malignancy in pancreatic cancer","volume":"8","author":"Grassilli","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0315","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.2174\/1381612821666150531165059","article-title":"Nanoparticle-based combination therapy for cancer treatment","volume":"21","author":"Yhee","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0320","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.addr.2017.04.003","article-title":"Nanoformulation-based sequential combination cancer therapy","volume":"115","author":"Shim","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0325","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.biomaterials.2017.08.036","article-title":"Polymeric nanoparticles of siRNA prepared by a double-emulsion solvent-diffusion technique: physicochemical properties, toxicity, biodistribution and efficacy in a mammary carcinoma mice model","volume":"145","author":"Ben David-Naim","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0330","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jconrel.2008.09.073","article-title":"A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles","volume":"133","author":"Cohen-Sela","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0335","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10616-009-9236-6","article-title":"Development of an optimized protocol for primary culture of smooth muscle cells from rat thoracic aortas","volume":"61","author":"Xu","year":"2009","journal-title":"Cytotechnology"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0340","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1016\/j.biomaterials.2011.01.021","article-title":"The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles","volume":"32","author":"Xiao","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-bioeng-071811-150124","article-title":"The effect of nanoparticle size, shape, and surface chemistry on biological systems","volume":"14","author":"Albanese","year":"2012","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0350","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/nnm.16.5","article-title":"The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction","volume":"11","author":"Hoshyar","year":"2016","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0355","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1016\/j.biomaterials.2010.01.065","article-title":"Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles","volume":"31","author":"He","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0360","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jconrel.2019.09.020","article-title":"Optimizing biodegradable nanoparticle size for tissue-specific delivery","volume":"314","author":"Mandl","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0365","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0168-3659(02)00127-X","article-title":"Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake","volume":"82","author":"Sahoo","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0370","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/mabi.201100145","article-title":"Poly(vinyl alcohol) physical hydrogels: new vista on a long serving biomaterial","volume":"11","author":"Alves","year":"2011","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0375","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/109158189801700505","article-title":"Final report on the safety assessment of polyvinyl alcohol","volume":"17","author":"Nair","year":"1998","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0380","first-page":"339","article-title":"Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations","volume":"9","author":"Escobar-Chavez","year":"2006","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0385","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030633","article-title":"Liposomal siRNA formulations for the treatment of herpes simplex virus-1: in vitro characterization of physicochemical properties and activity, and in vivo biodistribution and toxicity studies","volume":"14","author":"Jbara-Agbaria","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0390","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jcb.240560103","article-title":"Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation","volume":"56","author":"Kubota","year":"1994","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0395","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1097\/00006676-200305000-00020","article-title":"An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer","volume":"26","author":"Hotz","year":"2003","journal-title":"Pancreas"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0400","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.034793","article-title":"Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy","volume":"11","author":"Erstad","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0405","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0410","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3109\/10717541003777225","article-title":"Biodistribution of antisense nanoparticles in mammary carcinoma rat model","volume":"17","author":"Elazar","year":"2010","journal-title":"Drug. Deliv."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0415","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev-pharmtox-010611-134623","article-title":"Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective","volume":"52","author":"Moghimi","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0420","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0425","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay9249","article-title":"A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics","volume":"6","author":"Price","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0430","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/749010","article-title":"The glomerular filtration barrier: components and crosstalk","volume":"2012","author":"Menon","year":"2012","journal-title":"Int. J. Nephrol."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0435","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1002\/anie.201711705","article-title":"Imaging nano-bio interactions in the kidney: toward a better understanding of nanoparticle clearance","volume":"57","author":"Wang","year":"2018","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0440","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0445","doi-asserted-by":"crossref","first-page":"8548","DOI":"10.1016\/j.biomaterials.2011.07.067","article-title":"Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis","volume":"32","author":"Werner","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0450","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2011.11.025","article-title":"An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels","volume":"158","author":"Zahedi","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0455","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2021.03.028","article-title":"Polycation fluorination improves intraperitoneal siRNA delivery in metastatic pancreatic cancer","volume":"333","author":"Hang","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0460","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.biomaterials.2016.03.044","article-title":"A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma","volume":"93","author":"Indolfi","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0465","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0972-9941.33272","article-title":"Laparoscopy in pancreatic tumors","volume":"3","author":"Shrikhande","year":"2007","journal-title":"J. Minim. Access Surg."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0470","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2012.07.010","article-title":"Analysis on the current status of targeted drug delivery to tumors","volume":"164","author":"Kwon","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0475","doi-asserted-by":"crossref","first-page":"9594","DOI":"10.1021\/acsnano.7b04855","article-title":"Bridging bio-nano science and cancer nanomedicine","volume":"11","author":"Bjornmalm","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0480","doi-asserted-by":"crossref","DOI":"10.1007\/s11051-018-4273-8","article-title":"Nanoparticle transport pathways into tumors","volume":"20","author":"Moghimi","year":"2018","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0485","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.7150\/thno.38587","article-title":"Transcytosis - an effective targeting strategy that is complementary to \"EPR effect\" for pancreatic cancer nano drug delivery","volume":"9","author":"Liu","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0490","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.bpj.2016.03.040","article-title":"Interstitial pressure in pancreatic ductal adenocarcinoma is dominated by a gel-fluid phase","volume":"110","author":"DuFort","year":"2016","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0495","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1172\/JCI92284","article-title":"Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer","volume":"127","author":"Liu","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0500","first-page":"1","article-title":"Clinical biochemistry of hepatotoxicity","volume":"1","author":"Sharma","year":"2014","journal-title":"J. Clin. Toxicol."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0505","article-title":"Acute toxicity of amorphous silica nanoparticles in intravenously exposed ICR mice","volume":"8","author":"Yu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0510","article-title":"Understanding nanomaterial-liver interactions to facilitate the development of safer nanoapplications","volume":"34","author":"Li","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0515","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1097\/00005768-199711000-00005","article-title":"The poloxamer 407-induced hyperlipidemic atherogenic animal model","volume":"29","author":"Palmer","year":"1997","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0520","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/00005344-199912000-00010","article-title":"Potential downregulation of HMG-CoA reductase after prolonged administration of P-407 in C57BL\/6 mice","volume":"34","author":"Johnston","year":"1999","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0525","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00005344-200404000-00016","article-title":"The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date","volume":"43","author":"Johnston","year":"2004","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.01.084_bb0530","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/onc.2016.378","article-title":"TGF beta promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1","volume":"36","author":"Huang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2023.01.084_bb0535","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.devcel.2013.02.010","article-title":"Dynamin 2 potentiates invasive migration of pancreatic tumor cells through stabilization of the Rac1 GEF VAV1","volume":"24","author":"Razidlo","year":"2013","journal-title":"Dev. Cell"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:41:06Z","timestamp":1759164066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":107,"alternative-id":["S0168365923000937"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.084","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticles of VAV1 siRNA combined with LL37 peptide for the treatment of pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}